Incyte(INCY) - 2024 Q2 - Quarterly Results
Incyte(INCY)2024-07-30 11:15"In the second quarter of 2024, total revenues grew 9% year-over-year, surpassing 1.0 billion for the quarter. The commercial performance during this period was driven by strong patient demand for Opzelura (ruxolitinib) and growth across all indications for Jakafi (ruxolitinib)," said Hervé Hoppenot, Chief Executive Officer, Incyte. "In R&D, we completed a strategic review of our pipeline and have further intensified our focus on clinical programs that we believe can be transformational for patients. The ...